载药微球经动脉化疗栓塞术与常规经动脉化疗栓塞术治疗中晚期肝癌效果及安全性的meta分析  

Meta analysis of efficacy and safety of drug-eluting beads transarterial chemoembolization and conventional transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma

作　　者：曹博 张光文[2] CAO Bo;ZHANG Guangwen(The First Clinical College,Xinxiang Medical University,Henan Province,Xinxiang453000,China;Department of Infectious Diseases,the First Affiliated Hospital of Xinxiang Medical University,Henan Province,Xinxiang453000,China)

机构地区：[1]新乡医学院第一临床学院,河南新乡453000 [2]新乡医学院第一附属医院感染疾病科,河南新乡453000

出　　处：《中国医药导报》2021年第26期95-99,共5页China Medical Herald

基　　金：河南省科技厅科技攻关计划项目(172102310501)。

摘　　要：目的比较载药微球经动脉化疗栓塞术(DEB-TACE)与常规经动脉化疗栓塞术(cTACE)治疗中晚期肝癌的效果及安全性。方法检索PubMed、EMbase、Cochrane library、中国知网、万方、维普数据库中有关DEB-TACE和cTACE治疗中晚期肝癌的随机对照试验(RCT),检索时间为建库至2020年6月,应用Stata 15.1软件分析,比较治疗后的疾病控制率(DCR)、1年生存率、2年生存率及不良反应发生率。结果共纳入13项RCT研究,1478例患者。DEB-TACE组治疗后DCR高于cTACE组,差异有统计学意义(OR=2.18,95%CI:1.49~3.19,P<0.001)。DEB-TACE组1年生存率高于cTACE组,差异有统计学意义(OR=1.91,95%CI:1.32~2.75,P=0.001)。DEB-TACE组2年生存率高于cTACE组,差异有统计学意义(OR=1.70,95%CI:1.16~2.50,P=0.006)。两组不良反应率比较,差异无统计学意义(OR=0.74,95%CI:0.53~1.02,P=0.068)。结论DEB-TACE治疗中晚期肝癌的效果优于cTACE,安全性不劣于cTACE。Objective To compare the efficacy and safety of drug-eluting beads transarterial chemoembolization(DEB-TACE)and conventional transarterial chemoembolization(cTACE)in the treatment of advanced hepatocellular carcinoma.Methods PubMed,EMbase,Cochrane library,CNKI,Wanfang and VIP databases were searched for the randomized controlled trials(RCT)of DEB-TACE and cTACE in the treatment of advanced hepatocellular carcinoma.The retrieval period was from establishment of the database to June 2020,and the data were analyzed by Stata 15.1 software.The disease control rate(DCR)after treatment,1-year survival rate,2-year survival rate and adverse reaction rate were observed.Results A total of 13 RCTs with 1478 patients were included.The DCR after treatment of DEB-TACE group was higher than that of cTACE group,and the difference was statistically significant(OR=2.18,95%CI:1.49-3.19,P<0.001).The 1-year survival rate of DEB-TACE group was higher than that of cTACE group,and the difference was statistically significant(OR=1.91,95%CI:1.32-2.75,P=0.001).The 2-year survival rate of DEB-TACE group was higher than that of cTACE group,and the difference was statistically significant(OR=1.70,95%CI:1.16-2.50,P=0.006).There was no significant difference in the rate of adverse reactions between two groups(OR=0.74,95%CI:0.53-1.02,P=0.068).Conclusion DEB-TACE has better efficacy than cTACE in the treatment of advanced hepatocellular carcinoma,and its safety is not inferior to cTACE.

关 键 词：肝癌 经动脉化疗栓塞术 载药微球 META分析 

分 类 号：R735.7[医药卫生—肿瘤]